TODAY’S RESEARCH FOR TOMORROW'S HEALTH

SYREON

RESEARCH

INSTITUTE

Established in 2008, Syreon Research Institute is a research-driven organization striving to enhance unbiased, evidence-based research and decision-making in healthcare and nutrition science through multistakeholder collaborations on a local, European, and global level.

Since its inception, Syreon has delivered expert services in evidence synthesis, health economics, health policy, public health, modelling, food and nutrition science, and patient engagement. We also provide specialized training to public health institutes, the pharmaceutical industry, and health service providers.

Our network of partnerships includes an elite portfolio of global pharmaceutical corporations, emerging biotechnology companies, public health institutes, and academic networks. Through strategic alliances with Syreon Corporation (North America), Syreon Research Romania (Central & Eastern Europe), Syreon Middle East (Middle East and North Africa), and Syreon Research Africa (Sub-Saharan Africa), we extend our expertise worldwide.

Who we are

NEWS

May 15, 2026

Syreon Research Institute at ISPOR 2026

Syreon Research Institute will participate in the ISPOR Annual Meeting 2026, where our team will contribute to scientific discussions on AI, patient-centred research, health economics, and evidence generation. Our colleagues, Tamás Ágh, Antal Zemplényi, Attila Imre, Dalma Hosszú, Said Wani, and Balázs Babarczy will represent Syreon and have their research presented across eight conference sessions, including podium presentations, issue panels, and posters. 

March 31, 2026

COMPASS project kicks off to drive AI-powered innovation in cardio-oncology

Improving the heart health of people living with and beyond cancer has become a key concern for Europe. One in four anticancer medicinal products have required a safety warning related to cardiac or vascular side effects, creating new challenges for patients and healthcare systems as cancer survival continues to improve. In response, the European Union is prioritising earlier detection, integrated care pathways and the use of digital and artificial intelligence–enabled solutions to reduce cardiovascular complications.

February 5, 2026

Organisation for Economic Co-operation and Development (OECD) 2026 report – Delivering High-Value Cancer Care

Syreon Research Institute is proud to share that the Organisation for Economic Co-operation and Development (OECD) has published its 2026 report, Delivering High-Value Cancer Care, informed in part by evidence generated through the EuroACT project,...

January 28, 2026

DIGIT-PRE project – strengthening European digital health innovation

We are proud to share the successful closing of the DIGIT-PRE project and to reflect on the impact this collaboration has delivered for European digital health innovation. DIGIT-PRE set out...

MORE NEWS
Image
“

Thank you for the terrific draft epidemiology report! I have been reading the literature for quite some time now, and I found the draft report illuminating and informative. It reads well and provides useful epi data, summarized in a clear and succinct manner.

Associate Director of an International Company
“

A big thank you for giving the MEA seminar in our country. The content you covered was very much on point, relevant for our market, and clearly resonated with the audience.

Head of Oncology Policy and Market Access of Multinational Pharmaceutical Company
“

I wish to thank the Syreon Team for the continuous support they have been providing us across several years to ensure the success of the European launch of our product.

Strategic Marketing and Licensing Division of Global Pharmaceutical Company
“

This is a fabulous paper, beautifully constructed, and a wonderfully invaluable guide for future researchers. A little masterpiece of concision. Great job.

Professor Emeritus, US Medical University
“

Thank YOU very much for your excellent support.

Global International Health Organization
“

My deepest thank you to you and Syreon for delivering this ad hoc work on time and so well done. You don't know how much I appreciate having you as a resource to rely on.

Vice President of Multinational Pharmaceutical Company
“

Wow, my compliments to the entire team; your findings, once again, are incredible. Thank you!

Head of Market Access Division at a Pharmaceutical Company
Image